← Current Drug Targets - Immune Endocrine & Metabolic Disorders
Papers in Current Drug Targets - Immune Endocrine & Metabolic Disorders
Page 1 · newest first
- Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of PharmacogenomicsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Insulin Regulation of PEPCK Gene Expression: A Model for Rapid and Reversible ModulationCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Molecular Basis of Therapeutic Strategies for Breast CancerCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Failure of Immune Homeostasis - The Consequences of Under and Over ReactivityCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Signal Transducer and Activator of Transcription 5 (STAT5), a Crucial Regulator of Immune and Cancer CellsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human DiseasesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Caspases as Drug Targets in Ischemic Organ InjuryCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Advances in Osteoclast Differentiation and FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Signaling Processes in Tumoral Neuroendocrine Pituitary Cells as Potential Targets for Therapeutic DrugsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Myocardial Insulin Resistance and Cardiac Complications of DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Contribution of Canalicular Glutathione Efflux to Bile Formation. From Cholestasis Associated Alterations to Pharmacological Intervention to Modify Bile FlowCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Ion Transport Across the Gallbladder EpitheliumCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Effects of Endocrine Disruptors on Developmental and Reproductive FunctionsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Reduction of Hepatic Glucose Production as a Therapeutic Target in the Treatment of DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- CXCR3-binding Chemokines: Novel Multifunctional Therapeutic TargetsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Therapeutic Strategies To Prevent Neurodegeneration And Promote Regeneration In Multiple SclerosisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Regulation of the Steroidogenic Acute Regulatory Protein Expression: Functional and Physiological ConsequencesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2005
- Recent Advances in the Understanding of HIV-1 Vpu Accessory Protein FunctionsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Chemokine-Chemokine Receptor Network in Immune Cell TraffickingCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Functions of the HIV-1 Nef ProteinCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Therapeutic Targeting of Interactions Between Nef and Host Cell ProteinsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of PreventionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Controlling HIV-1 Rev FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Molecular Elements of Apoptosis-Regulating Pathways in Follicular Thyroid Cells: Mining for Novel Therapeutic Targets in the Treatment of Thyroid CarcinomaCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Redifferentiation Therapy in Advanced Thyroid CancerCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Activins, Myostatin and Related TGF-β Family Members as Novel Therapeutic Targets for Endocrine, Metabolic and Immune DisordersCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- The Pathobiology of Osteoarthritis and the Rationale for Using the Chondroitin Sulfate for its TreatmentCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill PatientsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Regulators of G Protein Signaling: Potential Drug Targets for Controlling Cardiovascular and Immune FunctionCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Immunological Modulation by Lidocaine-Epinephrine and Prilocaine- Felypressin on the Functions Related to Natural Immunity in Neutrophils and MacrophagesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- The HIV-1 Nef Protein: How An AIDS Pathogenetic Factor Turns to a Tool for Combating AIDSCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- HDL and Inflammation in AtherosclerosisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- DI-2-Ethylhexyl Phthalate and Endocrine Disruption: A ReviewCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for TherapyCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Evidence for a Putative Relationship Between Type 2 Diabetes and Neoplasia with Particular Reference to Breast Cancer: Role of Hormones, Growth Factors and Specific ReceptorsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Melatonin Role in Experimental ArthritisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2004
- Tissue-Specific Glucocorticoid Reactivating Enzyme, 11β-Hydroxysteoid Dehydrogenase Type 1 (11β-HSD1) - A Promising Drug Target for the Treatment of Metabolic SyndromeCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Dual Roles of Adiponectin / Acrp30 In Vivo as an Anti-Diabetic and Anti- Atherogenic AdipokineCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for ObesityCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- DGAT: Novel Therapeutic Target for Obesity and Type 2 Diabetes MellitusCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other DisordersCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Stearoyl-CoA Desaturase-1 and the Metabolic SyndromeCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Evidences for iNOS Expression and Nitric Oxide Production in the Human MacrophagesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Breast Cancer: Biological Characteristics in Postmenopausal Type 2 Diabetic Women. Identification of Therapeutic TargetsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Skin Photoprotection by Green Tea: Antioxidant and Immunomodulatory EffectsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic AgentsCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Do Antidotes for Acute Cyanide Poisoning Act on Mercaptopyruvate Sulfurtransferase to Facilitate Detoxification?Current Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Biosynthetic Pathways of Plastid-Derived Organelles as Potential Drug Targets Against Parasitic ApicomplexaCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Metformin and its Liver Targets in the Treatment of Type 2 DiabetesCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003
- Drug-Induced Aseptic MeningitisCurrent Drug Targets - Immune Endocrine & Metabolic Disorders · 2003